Theme B Proffered Paper Session 3: Treatment
Tracks
.
Monday, September 24, 2018 |
4:00 PM - 5:35 PM |
Grand Lodge (Level 1) |
Speaker
Prof Andrew Carr
Director - HIV and Immunology Unit
St Vincent's Hospital, Sydney
Success And Failure Of Initial Antiretroviral Therapy (Art) In Adults: An Updated Systematic Review Including 77,999 Subjects From 1994 To 2017
4:00 PM - 4:15 PMBiography
Professor Andrew Carr is a clinical immunologist and immunopathologist, and Head of the HIV, Immunology and Infectious Diseases Unit and of the Clinical Research Program, Centre for Applied Medical Research, St Vincent’s Hospital, Sydney. He has authored more than 300 peer-reviewed publications, mostly on antiretroviral complications and comorbidities.
Dr Jillian Lau
Infectious Diseases Physician
Doherty Institute
Antiretroviral Treatment Interruptions In HIV Clinical Trials: A Systematic Review
4:15 PM - 4:30 PMBiography
Jillian Lau is an Infectious Diseases Physician who has an interest in HIV cure research, in particular antiretroviral treatment interruptions in HIV cure clinical trials. She is completing a PhD exploring social and clinicial research into HIV cure.
Dr David Baker
Director
East Sydney Doctors
Durable Suppression 2 Years After Switch To Dolutegravir + Rilpivirine 2-Drug Regimen: Sword 1&2 Studies
4:30 PM - 4:45 PMBiography
Dr David Baker has worked for over 20 years in a high HIV case load General Practice, he's a senior lecturer at the University of Notre Dame and a clinical advisor to ASHM. He has a special interest in the care of people who inject drugs and in HIV-HCV co-infection.
Prof Don Smith
Senior staff Specialist
The Albion Centre
Switch To Bictegravir/F/TAF From DTG And ABC/3TC
4:45 PM - 5:00 PMBiography
Don Smith's research interests include the impact of antiretroviral therapy at different stages of disease is of interest. International collaborations have concentrated on the effects of therapy during primary HIV infection on immunological and virological outcomes.
Dr David Baker
Director
East Sydney Doctors
Phase 3 Randomised, Controlled Trial Of Switching To Fixed-Dose Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) From Boosted Protease Inhibitor-Based Regimens In Virologically Suppressed Adults: Week 48 Results
5:00 PM - 5:15 PMBiography
David Baker has worked in Darlinghurst for over twenty years. He has a special interest in Sexual Health and HIV Medicine as well as Addiction Medicine and Hepatitis C. David has completed additional training at University of Sydney – the Diploma in Medicine (Sexual Health).
Rainer Puhr
Statistician
The Kirby Institute
Dr Timothy Barnes
General Practitioner
Holdsworth House Medical Practice
High HBV And HIV Suppression With Treatment Of HIV/HBV Coinfection In B/F/TAF Studies
5:30 PM - 5:35 PMBiography
Dr Tim Barnes joins Holdsworth House having spent the previous eight years consulting in HIV medicine at The Albion Centre. Prior to this he worked for many years in general practice in Sydney following residency at Sydney Hospital.
Chair
Craig Cooper
Executive DIrector
Northern Territory AIDS & Hepatitis C Council
Kate Mackie
Senior Clinical Pharmacist
Alfred Health